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Background
Human trafficking is a grave human rights violation and a major
public health concern. Survivors present with high rates of
mental health problems including post-traumatic stress disorder
(PTSD). Studies of effective treatments for PTSD in survivors of
human trafficking are lacking. Narrative exposure therapy (NET)
is an effective PTSD treatment for multiple, prolonged and
complex trauma, but its efficacy has not been rigorously tested
in survivors of human trafficking.
Aims
To test the feasibility and acceptability of a randomised con-
trolled trial (RCT) offering NET as a treatment for PTSD in traf-
ficking survivors with a history of multiple traumatic events, as
well as providing preliminary evidence regarding its efficacy (trial
registration: ISRCTN95136302).
Method
A single-blind RCT compared NET with a wait-list control in sur-
vivors of trafficking with PTSD (n = 25). In the NET arm of the
study, participants attended a mean of 17 sessions.
Results
NET was well tolerated by participants. There were significant
reductions in PTSD, depression and anxiety symptoms post-
treatment in the NET group but no significant change in the wait-
list group.
Conclusions
The results indicate that NET is a promising and acceptable
treatment for trafficking survivors. Psychological therapy in an
RCT design can be safely delivered to this vulnerable group,
although modifications are required to ensure their holistic
needs are properly addressed.
Keywords
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Human trafficking, the recruitment of people within or across
national borders for the purposes of exploitation, is a grave
human rights violation and a major public health concern.
Although its scale is hard to quantify, as of 2016, an estimated
24.9 million people were trafficked into different types of exploit-
ation globally.1 Individuals are exploited for a range of purposes
including forced labour, illegal drug cultivation, domestic work
and forced sex work. Many survivors of trafficking endure pro-
longed periods of exposure to hazardous conditions, abuse and vio-
lence, captivity and restriction of movement, as well as restricted
access to adequate nutrition or healthcare.2 Trafficked individuals
typically experience multiple or repeated traumatic events, includ-
ing physical violence, sexual abuse, and threats to them and their
loved ones.3 Systematic reviews have demonstrated a high preva-
lence of physical and psychological health problems in survivors
of trafficking, including depression, anxiety and post-traumatic
stress disorder (PTSD).3
In addition to the high prevalence of mental health problems,
many trafficking survivors face significant barriers to accessing evi-
dence-based treatments. These include destitution, homelessness
and legal stressors, as well as feelings of fear, shame and mistrust
of others, which can prevent help-seeking.4
In spite of calls for trafficking survivors to be provided with
comprehensive and culturally appropriate healthcare, and despite
recent advances in the literature around the risk and protective
factors for the development of psychopathology in this population,
there is a dearth of research into effective treatments.5,6 Efficacy and
real-world effectiveness studies are needed to develop and validate
evidence-based therapies for this extremely vulnerable group.
Narrative exposure therapy (NET) is an evidence-based treat-
ment for PTSD relating to multiple or prolonged traumatic
events.7–9 Through detailed narration, NET processes and contex-
tualises traumatic memories and helps individuals to establish a
coherent autobiographical narrative of their experiences.10 NET
has been widely used in lower- and higher-income countries and
with a range of different client groups, including asylum seekers
and refugees.11,12 NET is therefore a good candidate for treating
PTSD in survivors of human trafficking. A case series with ten
female trafficking survivors with a history of sexual exploitation
(who received 10–19 NET sessions) found preliminary evidence
for its acceptability and effectiveness.13 Treatment resulted in sig-
nificant reductions in PTSD severity and general distress, which
were maintained at 3 month follow-up. Although this indicated
potential utility, the case study design limited the generalisability
of the results, and it was not clear whether survivors of other
types of trafficking might benefit from this intervention.
The current study investigates NET as a treatment for PTSD in
trafficking survivors using a randomised controlled trial (RCT)
design. Given the barriers to treatment that trafficking survivors
may encounter, and the limited literature regarding how best to
meet their needs, we aimed to explore the feasibility of delivering
NET in an RCT in a real-world clinical setting.
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Aims of this study
The primary aim of the study was to explore the feasibility of con-
ducting an RCT investigating the effectiveness of NET in treating
PTSD in survivors of trafficking. The study was designed to:
(a) explore the acceptability and feasibility of delivering NET to
this population within an RCT;
(b) evaluate the process of recruitment and randomisation and the
acceptability of including a wait-list control;
(c) determine the feasibility of delivering psychological therapy in
the absence of specific additional provision of practical support.
Our secondary aim was to investigate the effectiveness of NET
in reducing PTSD, depression and anxiety symptoms in trafficking
survivors.
As a feasibility study, the sample was potentially insufficiently
powered; however, the study was designed to examine the feasibility
of testing whether participants receiving NET would show a greater
reduction in their PTSD symptoms (clinician-assessed and self-
reported symptoms) and in any comorbid symptoms of depression
and anxiety compared with those in the wait-list group.
Method
Trial design
The trial was a single-centre, blinded, two-armed feasibility RCT
with parallel groups: NET and wait-list control (trial registration:
ISRCTN95136302).
Participants
Participants were survivors of trafficking (involving various or mul-
tiple forms of exploitation) with a diagnosis of PTSD. Treatment
was offered by therapists working at a UK-based charity providing
specialist care to individuals who have experienced human rights
abuses. This includes psychological therapy, as part of a holistic
model of integrated care including legal protection, counter-traf-
ficking safeguarding support, housing and welfare advice, and
access to educational and social inclusion activities.
Participants were recruited between May 2017 and September
2018 via two pathways (Fig. 1). They were either existing clients
of the charity and in receipt of the organisational model of care,
or referred by external professionals specifically to receive psycho-
logical treatment within the trial (i.e. ‘trial-only’ participants)
without access to other aspects of the organisation’s support.
All potential participants referred to the study were invited to
attend an assessment appointment with a trial therapist.
Participants were not offered any incentive for participating in the
trial. Travel expenses were reimbursed.
Inclusion criteria were kept as broad as possible: adult survivors
of trafficking meeting DSM-5 diagnostic criteria for PTSD;14 not
having received any type of trauma-focused therapy previously;
and willing to engage in NET. Exclusion criteria included: recent
suicide attempt or persistent severe self-harm; significant and fre-
quent substance misuse; severe preoccupation with social or legal
issues that would interfere with engagement in regular therapy ses-
sions; facing imminent removal from the UK; or currently in a situ-
ation of abuse or exploitation.
Fifty-five individuals were assessed for trial suitability during a
face-to-face assessment with a clinician; 26 met the study inclusion
criteria and gave informed consent to participate. One individual
was not progressed in the study owing to instability in their
circumstances arising following assessment (Fig. 3). Twenty-five
participants were randomly assigned to receive NET immediately
(n = 15) or to a wait-list control group (n = 10). In total, 13
participants completed NET, and seven completed the waiting
period (and post-wait assessments). Table 1 shows the sociodemo-
graphic variables of the sample at the point of randomisation and
the ‘main’ types of trafficking experienced by participants (self-
identified). Many had experienced multiple forms of exploitation
or other traumatic experiences at various points in their life. All
participants completed the Life Events Checklist15 as part of their
assessment and reported a range of traumatic experiences both
within and beyond their experiences of trafficking, including
sexual violence, physical assault and witnessing the death of a
family member or significant other. However, all participants
identified the traumas associated with their period of trafficking
as among the primary traumatic experiences that they wanted to
address in treatment.
Outcome measures
The main clinical outcome in the study was overall PTSD symptom
severity, measured through a clinician-administered diagnostic
assessment and a self-report scale.
The Clinician-Administered PTSD Scale (CAPS-5)16 is the
‘gold-standard’ clinician-administered structured diagnostic inter-
view for PTSD. Items are rated from 0 (absent) to 4 (extreme/incap-
acitating) with a maximum possible score of 80. Different cut-offs
have previously been suggested to indicate clinically significant
change on the CAPS-5.17 Given our small sample size and the rela-
tively high variability in scores, we deemed it inappropriate to apply
a very stringent method of assessing reliable change (two standard
deviations from the mean) and instead used Halvorsen’s17 other
suggested method: a change of >30% from baseline score.
The PTSD Checklist for DSM-5 (PCL-5)18 is a 20-item self-
report measure of PTSD symptom severity. Items are rated from
0 (not at all) to 4 (extremely) based on the frequency or impact of
the symptom. A sum score was calculated for PTSD severity
(maximum score = 80). Suggested clinical cut-offs for this
measure are scores of 31−33.19 As participants had experienced
multiple traumatic or difficult life experiences, they were reminded













Fig. 1 Referral pathway.
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identified during completion of their psychological and CAPS-5
assessments when providing their responses to the PCL-5.
Secondary clinical outcome measures
The Shutdown Dissociation Scale (Shu-Dis)20 is a 13-item measure
of the physical signs of dissociation. This measure was included
because of its clinical utility in NET, as it indicates the potential like-
lihood of dissociation, as well as common signs and symptoms that
will need to be managed and addressed during therapy. Items are
scored from 0 (not at all) to 3 (several times a week/often) depend-
ing on the current frequency of symptoms. A sum score was calcu-
lated for dissociation severity (maximum score = 39).
The Patient Health Questionnaire (PHQ-9)21 and the
Generalized Anxiety Disorder Scale (GAD-7)22 are, respectively, a
nine-item measure of depression and a seven-item measure of
anxiety severity. They are both widely used and have been validated.
Items are scored from 0 (not at all) to 3 (nearly every day). A sum
score was calculated for symptom severity (depression maximum
score = 27; anxiety maximum score = 21).
Procedure
This trial was designed to comply with the ethical standards of the
relevant national and institutional committees on human
experimentation (and with the Helsinki Declaration of 1975, as
revised in 2008). The study was approved by the ethics committee
of University College London (813/002). The procedure is sum-
marised in Fig. 2.
In view of their past experiences of exploitation, ensuring parti-
cipants could give informed (written) consent was crucial.
Participants were provided with detailed verbal and written infor-
mation, with professionally trained interpreter assistance where
required. Multiple opportunities to withdraw consent were pro-
vided prior to commencing and during the study.
After diagnostic assessment and completion of baseline
outcome measures, a research assistant randomised participants
to either trial condition using a virtual coin toss programme.
Clinical outcome measures were collected at baseline (pre-treat-
ment), midway through treatment or the wait-list period, and at
the end of treatment or the wait-list period. Standardised transla-
tions of the outcome measures were not consistently available in
all languages required by participants. Interpreters were therefore
used to complete standardised outcome measures where required.
Participants randomised to the wait-list condition were offered
NET after the study had concluded.
The aimwas for all assessors working on the study to remain blind
to allocation throughout the trial. Individuals allocated to the wait-list

























Fig. 2 Study procedure.
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Intervention
Irrespective of treatment condition, each participant was initially
offered three sessions of protocolised psychoeducation about PTSD
symptoms and symptom management strategies (broadly similar
to that described in previous literature23). The standard NET proto-
col suggests only one session of psychoeducation.8,9 However, given
the high clinical need of this population, we offered three sessions to
increase the safety and acceptability of the waiting period for those
randomised to the wait-list condition. Psychoeducation sessions
were delivered by NET therapists and trained assistant psychologists.
Interpreters were used where required. Participants then entered
either the wait-list or the intervention phase.
NET sessions were delivered by seven female psychological
therapists (six clinical psychologists and one psychotherapist); all
had training and prior experience in working with survivors of traf-
ficking and in delivering NET (trained by F.B., E.W. and K.R. and
supervised by F.B. and E.W.). Treatment fidelity was monitored
through the recording of therapy sessions and regular case supervi-
sion by clinical psychologists with extensive experience of NET.
Sessions lasted 90 to 120 min and were offered on a weekly basis.
The first session of NET involved co-construction of a lifeline, in
which the participant and the therapist construct a chronological over-
view of the events of the participant’s life, including traumatic experi-
ences.8,9 A therapy plan was then constructed collaboratively, taking
into account themaximumnumber of 20 sessions available as dictated
by the study protocol. This maximum number was agreed on by the
authors in line with guidance provided by a clinician with expertise
in NET (K.R.) and the available clinical resources. As directed by
the NET manual, the majority of time in sessions was spent on facili-
tation of the participant’s detailed narration of their traumatic experi-
ences to ‘process’ the trauma memory, facilitate attachment repair,
and make meaning of their traumatic and adverse experiences.
Where time permitted, positive life events were also explored. A
written narrative was created following the therapy sessions; this
was read back and given to participants in the final therapy session.
Owing to the potential for instability or changes in the partici-
pants’ social and legal circumstances, a maximum of four additional
non-NET sessions were also available for therapists to offer at their
discretion to address any urgent or risk issues arising during treat-
ment (see Results section).
Feasibility
The study was intended to explore the feasibility of implementing a
subsequent RCT. Our decision-making was informed by feasibility
trial evaluation guidelines known as the ADePT Framework.24
Accordingly, we considered barriers to a large-scale trial, amend-
ments needed to improve the success of a follow-on RCT, and the
practicality of addressing these. These questions were considered
in determining whether a follow-on RCT would be (a) feasible,
(b) feasible with amendments or (c) not feasible.
Data analysis
To investigate any change between pre-treatment and post-treat-
ment across the intervention and the control group, we ran analyses
of covariance (ANCOVA) for each outcomemeasure while control-
ling for baseline levels (in line with previous studies25,26).
Results
Feasibility
The ADePT framework24 was used to evaluate the feasibility
outcomes of the study.
Recruitment, sample size and retention
Details of participant flow and retention are shown in Fig. 3.
Initially, we aimed to recruit 30 participants for the trial.
Ultimately, 55 people were assessed, but 29 individuals did not
meet the inclusion criteria for the following reasons: not having a
diagnosis of PTSD (n = 10); not attending appointment(s) (n = 4);
in crisis/high suicide risk (n = 2); previously received trauma-
focused therapy (n = 2); preoccupation with instability in social or
legal circumstances (n = 1); or still in exploitation (n = 1, necessary
safeguarding procedures were followed). A further nine
individuals met the inclusion criteria but declined to participate in
the study for the following reasons: not wanting to engage in
trauma-focused therapy at the time (n = 7); not willing to travel
for appointments (n = 1); and not consenting to recording of
therapy sessions (n = 1). Trial recruitment took longer than
expected (approximately 16 months) and had to be concluded
before the target number of 30 participants had been recruited.
However, recruitment was sufficient overall to enable evaluation
of feasibility.
Randomisation did not yield equal allocation across the two
groups. There were also some notable group differences in the distri-
bution of other participant characteristics, including whether the par-
ticipant was an English speaker, and in terms of country of origin.
Overall, retention in both arms of the trial was acceptable.
Within the NET group, one individual discovered that she was in
the advanced stages of pregnancy soon after allocation. It was not
feasible for her to receive a full course of treatment, so she was with-
drawn from the study. One individual dropped out of therapy after
eight sessions, stating that they no longer wanted to engage in
trauma-focused therapy. All other participants in the NET group
(n = 13) completed NET.
In the wait-list group, one participant was removed from the
trial before the end of the waiting period owing to a significant
increase in their risk of suicide. The remaining participants in the
wait-list group completed the waiting period. However, two partici-
pants dropped out of the study at the point of post-wait assessment,
owing to a deterioration in their physical health, and were therefore
lost to follow-up. The remaining participants in the wait-list group
were offered the opportunity to receive NET, and all took up this
offer.
Protocol adherence
Overall, the procedures set in place at the outset worked well during
the study. Outlined below are the key areas of the protocol where
significant challenges arose.
Intervention
NET was generally perceived by participants to be an appropriate
and acceptable treatment for their psychological difficulties.
However, seven individuals declined to take part in the study
because they did not feel ready to engage in a trauma-focused inter-
vention at the point it was offered. One individual dropped out
during therapy, citing the same reason. The reasons behind these
decisions mostly related to feeling too unsettled in their social cir-
cumstances to focus on trauma therapy.
In all but one case, NET was delivered within the anticipated
time frame of a maximum of 20 sessions (range 13–26 sessions).
No substantial issues arose with regards to therapist adherence to
the treatment model. Participants received a mean of 17 sessions
of NET (s.d. = 4.07) across a mean of 220.6 days (s.d. = 65.27;
approximately 7.4 months). This timeframe was longer than the
5–6 months anticipated. The main contributing factor to this was
the varied regularity in session attendance, with a mean of 2.5
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cancelled or non-attended sessions (range = 0–9) per participant
over the course of therapy.
To ensure that we could fulfil the recruitment aims of the study,
the trial included participants who were not able to access holistic
support from the organisation to address other practical needs
(owing to capacity limitations across the organisation). Many of
these ‘trial-only’ participants had significant legal and social
needs, but few had regular access to support agencies who could
provide robust assistance with these issues.
Of those who completed NET, ‘trial-only’ participants (n = 6)
received a mean of 2.67 (s.d. = 2.07) additional sessions to address
other problems (such as newly arising legal and social problems,
risk or mental health crises), compared with 1.71 (s.d. = 1.70) for
those who had access to holistic support through the organisation
(n = 7). The range was 0–5 across both groups. In the absence of
other sources of support, therapists anecdotally reported needing
to engage in other advocacy activities for participants, including pre-
paring clinical letters in relation to immigration or housing issues.
The importance of offering holistic support alongside psychological
therapy is explored in more detail in the Discussion section.
Assessments and data collection
The measures used appeared to be acceptable for participants and
provided useful information about key clinical outcomes.
Assessments of participants’ PTSD symptoms necessitated speaking
about their trauma. Assessments were conducted by trained clini-
cians who could support participants if they became emotionally
distressed. This procedure should be maintained for any future
trial, given the extent of participants’ trauma histories.
Assessed for eligibility
(n = 55) 
Excluded (n = 30)
®  Did not meet inclusion criteria (n = 20)
®  Declined to participate (n = 9) 
®  Change in stability of circumstances (n = 1)
Analysed (n = 13)
®  Excluded from analysis (n = 0)
Lost to follow-up (n = 2)
®  Withdrawn − new pregnancy (n = 1) 
®  Dropped out of treatment (n = 1)
Allocated to NET intervention (n = 15)
Started NET intervention (n = 14)
Lost to follow-up (n = 3)
®  Withdrawn − increase in risk (n = 1)
®  Dropped out due to deterioration in
     physical health (n = 2) 
Allocated to wait-list control (n = 1 0)
Completed waiting period (n = 9) 
Analysed (n = 7)




Randomized (n = 25)
Enrolment
Fig. 3 CONSORT participant flow diagram.
Table 1 Demographic characteristics of sample (at baseline) N (%) or
mean (s.d.)
Variables
NET (n = 15) Wait-list (n = 10)
N (%) N (%)
Sex
Male 4 (26.66) 2 (20.00)
Female 11 (73.3) 8 (80.00)
Interpreter required 5 (33.33) 7 (70.00)
Asylum status
Refugee status or leave to
remain
2 (13.33) 3 (30.00)
Asylum seeker 12 (80.00) 7 (70.00)
Appeal rights exhausted 1 (6.66) 0 (0)
Primary type of exploitation
Sexual exploitation 8 (53.33) 7 (70.00)
Forced labour 4 (26.66) 2 (20.00)
Domestic servitude 2 (13.33) 1 (10.00)
Other 1 (6.66) 0 (0)
Country of origin
Nigeria 7 (46.66) 0 (0)
Albania 3 (20.00) 6 (60.00)
India 1 (6.66) 1 (10.00)
Nepal 1 (6.66) 0 (0)
Vietnam 1 (6.66) 0 (0)
China 1 (6.66) 1 (10.00)
South Africa 0 (0) 1 (10.00)
Kenya 0 (0) 1 (10.00)
Philippines 1 (6.66) 0 (0)
Trial-only participants 8 (53.33) 6 (60.00)
Mean age at start of trial 26.73 years (s.d. =
9.35)
32.8 years (s.d. =
10.96)
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Not all assessments were completed at all time points. Some par-
ticipants dropped out because of a change in their circumstances. Some
reported finding the length of assessment appointments and the
number of assessments challenging. At times, participants did not pri-
oritise attending these appointments, particularly in the follow-up
period, once treatment was complete. Proactive engagement from
the research team was required to encourage individuals to attend
assessments. Despite these efforts, there were some delays or gaps in
data collection, and some participants were lost to follow-up. No finan-
cial incentives were offered in this study. However, future studies
should consider offering small financial or other incentives for
participants to reimburse them for the time spent attending research
assessments. This would recognise the vital contribution of the
survivors to the research and hopefully improve data completeness.
Adherence to blinding
The study research coordinator attempted to keep clinicians con-
ducting assessments and outcome measures blind throughout the
trial to minimise bias risk. Maintaining blinding was difficult
within a small clinical team, and was a particular challenge
because of the organisation’s regular work activities, which some-
times resulted in a therapist having clinical contact with participants
for non-trial reasons. Unblinding therefore occurred in several
cases, either ‘accidentally’ (e.g. the assessor had encountered the
participant attending for a therapy appointment) or because the
participant made a disclosure during an assessment session,
despite being asked not to do so. Larger-scale studies would
benefit from having dedicated trial therapists or assessors to facili-
tate blinding adherence.
Clinical outcomes
Given that this was a feasibility study with only a small sample and
some missing data, we analysed completer data rather than
performing an intention-to-treat (ITT) analysis. We would recom-
mend that future full-scale RCTs are sufficiently powered that ITT
analysis is possible.
In terms of baseline scores, t-tests revealed no significant differ-
ences on the outcomemeasures across the two groups, except for the
Shu-Dis (t = 2.19, P = 0.04), with those in the wait-list group report-
ing more dissociative symptoms (see Discussion section). A
summary of the scores at baseline and endline (end of treatment
or end of waiting period) can be seen in Fig. 4. Three data points
were missing from the final analysis: two participants’ CAPS
scores at baseline (one in the NET group, one in the wait-list
group) and one endline PCL-5 score (NET group). Where data
were missing, these participants were excluded from these specific
analyses.
To investigate changes between baseline and endline across the
NET and wait-list groups, we conducted ANCOVA for each
outcome measure while controlling for baseline scores.
In line with our a priori hypothesis, there was a significant
decrease in the scores of all outcome measures between pre- and
post-treatment in the NET group (Table 2). However, in the wait-
list group, no such change was observed and scores on most out-
comes remained stable or increased slightly.
No formal power calculation was completed for this feasibility
study. However, the above results indicate a magnitude of change
in scores on both the CAPS-5 and PCL-5 (the primary outcome
variables) in the NET group that is statistically significant and
reflects a large effect size (Cohen’s d = 2.36).
In terms of clinically significant change in the NET group, 50%
of individuals in the NET group (n = 12 owing to missing data)
showed clinically significant change in their endline CAPS-5
scores. Of the remainder, two participants (16.6%) showed some
worsening in scores, but this was not clinically significant. All











Control Intervention Control Intervention Control Intervention Control Intervention Control Intervention
CAPS PCL-5 Shu-Dis PHQ-9 GAD-7
Baseline
Endline
Fig. 4 Scores for NET and wait-list groups at baseline and endline.
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Using the criteria outlined above, we also explored clinically sig-
nificant change on the PCL-5 in the NET group. The results indi-
cated that 83% of participants (n = 12 owing to missing data)
showed clinically significant improvement in their self-reported
PTSD symptoms at endline. Of the remaining two participants,
one reported symptomatic improvement which was not clinically
significant, and another reported a slight worsening of symptoms,
although symptoms were only just above diagnostic threshold
even at baseline.
Discussion
Survivors of human trafficking experience multiple forms of abuse
and suffer a range of health consequences.2,3 There is limited evi-
dence relating to effective treatments for this complex and highly
vulnerable group, and little is known about their ability to engage
in psychological therapy.
This feasibility study shows that evidence-based psychological
interventions can be implemented successfully with trafficked indi-
viduals with a chronic trauma history, even while they continue to
experience uncertainty and instability in their immigration and
social circumstances. The low attrition rate indicates that NET
was perceived to be an acceptable treatment by trafficking survivors.
The results are promising and suggest that NET is a viable treatment
for survivors of trafficking that warrants further evaluation in full-
scale RCTs.
However, a number of clinical and procedural issues would
require consideration in any future trials involving trafficking
survivors.
Clinical issues
Although participant recruitment and retention were acceptable, a
number of individuals were not sufficiently stable or declined to
participate in a trauma-focused intervention. This is in keeping
with the emergent literature on the provision of psychosocial care
to survivors of trafficking, which suggests that their other (often sig-
nificant) needs, including safety, social and legal needs, must be
addressed alongside any mental health treatment.27
Comprehensive case management to address the full range of psy-
chosocial needs of the survivor is important to support positive clin-
ical outcomes. However, many participants completed (and
benefited from) NET despite their ongoing practical problems.
This suggests that ongoing legal and social problems are not neces-
sarily a barrier to an individual’s engagement with a trauma-focused
intervention.
A collaborative approach, with respect for survivors’ autonomy,
is considered to be another pillar of clinical interventions for traf-
ficking survivors. Providing detailed information about treatment
and supporting survivors to make an informed choice about their
care is particularly important for this population. A key challenge
in delivering an RCT with this population was the lack of flexibility
in how and when treatment could be offered, which is known to be
an important consideration when working clinically with this
group.4,6 Although uptake of and engagement with the intervention
within the constraints of the RCT were generally good, further con-
sideration should be given to how the RCT protocol might be
adapted to include more flexibility for individuals who are also
dealing with substantial social problems, for example, offering a
staggered baseline design.
Although NET brought about a reduction in both PTSD and
other psychological symptoms, some clinical issues emerged that
require further exploration in future research. The participants
were quite heterogenous as a group: some reported a long trauma
history that extended beyond their trafficking experiences,
whereas others had fewer or more time-limited exposures to
trauma. This led to high variability in baseline and outcome
scores and made it difficult to draw conclusions that would be
fully generalisable to survivors of all types (or lengths) of trafficking.
It also necessitated decisions about which traumatic events could be
addressed within a limited number of sessions. This was sometimes
challenging both for participants and therapists. Trafficking often
leaves individuals with significant trust difficulties, but the limita-
tions of the trial necessitated therapists to quickly develop a trusting
working alliance with the participants. As above, consideration
should be given to where it might be possible to introduce flexibility
into the treatment protocol to optimally facilitate survivor engage-
ment in trauma-focused treatment.
In addition, the impact of shame in the maintenance of PTSD
symptoms (and as a barrier to engagement with trauma-focused
treatment) frequently arose as a theme in therapy sessions and in
the therapists’ supervision sessions. This is in keeping with previous
research,10,13 which also highlights shame as a key difficulty for traf-
ficking survivors. This issue may benefit from further exploration in
future research, for example, ascertaining whether any particular
adaptations to the standard NET protocol might be helpful for
this group. However, of note is that the final outcomes were post-
treatment, whereas research28 indicates benefits of NET over
longer follow-up periods.
Further research should include a follow-up period and could
also explore the experience of trafficking survivors undertaking
NET and factors that influence decision-making around engaging
in treatment. Consideration should also be given to developing
and trialling alternative interventions (drawing on the existing evi-
dence base) that might help meet the needs of trafficking survivors
with symptoms of PTSD who do not yet feel ready to engage with
trauma-focused therapy.
Impact of practical needs of trafficking survivors
Owing to the study’s relatively flexible inclusion criteria, only two
individuals were excluded from the trial on the grounds of preoccu-
pation with social or legal issues. The majority of participants had
unresolved immigration claims at the point of entry to the trial.
We had anticipated delivering treatment in the absence of inte-
grated holistic support, but inconsistency in participants’ access to
practical support (including legal protection) was a key challenge
in this study. For individuals who did not have access to the organi-
sation’s holistic model of care, the therapist was often the sole pro-
vider of care and undertook additional advocacy activities to ensure
the participant’s safety and stability. At times, this advocacy work
was also required to manage wavering engagement in NET due to
preoccupation with legal and welfare issues.
Table 2 ANCOVA results
Coefficient 95% CI
NET v. wait-list −18.42** [−30.21, −6.62]
PCL-5 (n = 18)
NET v. wait-list −30.90*** [−42.16, −19.64]
Shu-Dis (n = 20)
NET v. wait-list −16.21*** [−21.76, −10.63]
PHQ-9 (n = 20)
NET v. wait-list −12.74*** [−16.60, −8.88]
GAD-7 (n = 20)
NET v. wait-list −10.35*** [−14.70, −6.00]
GAD-7, seven-item Generalised Anxiety Disorder Scale; PHQ-9, nine-item Patient Health
Questionnaire.
**P < 0.01, ***P < 0.001.
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Although we had anticipated that trafficking survivors would
have additional practical needs, we had expected that ‘trial-only’
participants would be able to access alternative sources of practical
support in the community during the course of therapy (such as via
the agency that referred them into the trial). However, very few
‘trial-only’ participants were able to access adequate practical
support, and they relied heavily on their trial therapist, which had
not been expected at the design stage of the study. The sample
size was too small to make meaningful comparisons in relation to
this (although the number of trial-only participants was distributed
relatively evenly across the NET and wait-list groups). During the
implementation of the trial, we decided that it was clinically uneth-
ical not to provide equal access to support for urgent needs (e.g. for
legal or housing issues); the trial therapists therefore spent time not
recorded in the session total ensuring these needs were met (e.g.
through writing clinical letters). We also did not record the
amount of contact that the organisational clients may have had
with other team members in order to address any practical needs.
This is a limitation and may have affected our clinical outcomes
because some individuals may have accessed more support than
others during the treatment or wait-list period.
We have reflected on how future studies might address this
issue. The main challenge in manualising access to practical
support is the unpredictability of needs. Even individuals with
leave to remain in the UK and relatively stable circumstances at
trial commencement were not exempt from experiencing significant
unpredictable problems (e.g. housing or financial crises) over the
course of the project. We suggest that to strike a balance between
methodological rigour and clinically ethical practice, it is important
that ad hoc practical support is available to all participants, rather
than participants being offered a manualised ‘dose’ of practical
support sessions. It will also be crucial to monitor how and when
such support is utilised by participants in a future study to
explore what (if any) relationship this has with treatment outcomes.
There is an ethical question about the appropriateness of a wait-
list control for trafficking survivors in unstable psychosocial cir-
cumstances. Two participants in the wait-list group were too
unstable to take up therapy when it was later offered owing to deteri-
oration in their circumstances. This issue should be considered care-
fully both in future RCTs and in clinical settings, where it might be
prudent to prioritise survivors of trafficking on therapy waiting lists
so that therapy is offered at a time when the individual is in a period
of relative stability. At a minimum, it is important that survivors
have ready access to ad hoc holistic support throughout any
waiting period, which might reduce the risk of people destabilising
or dropping out before therapy can be offered.
A key clinical recommendation of this study is that psycho-
logical support for trafficking survivors should be provided within
the context of multidisciplinary support. This is likely to promote
sustained engagement with psychological treatment and conse-
quently more optimal outcomes from therapy. This is echoed in lit-
erature4,13,27 which notes that beyond psychological treatment,
there is a need for trafficking survivors to access adjunctive
support, to promote safety and stability and reduce the risk of
future exploitation. Future RCTs should therefore make provision
for multidisciplinary support to flexibly address the holistic needs
of participants within the trial context.
Procedural issues
The clinical setting of the trial led to some challenges with delivering
the RCT protocol and assessments exactly as planned. One issue was
that randomisation did not bring about an even distribution of key
demographic characteristics of the participants across the groups,
which could have influenced the results. Of particular note, a
significant difference in scores on the Shu-Dis (self-rated dissoci-
ation symptoms) was found between the groups at baseline. This
may have influenced the results of the study and may be relevant
to treatment outcomes. Future studies should therefore consider
using stratification to ensure better matching between groups,
including on factors such as level of dissociative symptoms. In add-
ition, although the clinical findings of this study are promising, the
small sample size may have inflated the magnitude of the effect size,
so further studies with a larger sample are required. Similarly, the
immediate post-treatment improvement for NET clients may
have been a placebo effect, and post-treatment follow up of at
least three months should be included in future trials.
Another threat to the validity of the treatment outcomes was the
use of interpreters to translate outcome measures in the study.
Although this was necessary to avoid excluding non-English speak-
ers from the study, the lack of availability of standardised transla-
tions of these measures may have led to bias in translation or
understanding of measures. This may have affected the overall
results of the study. Future trials should endeavour to use standar-
dised translations of outcome measures wherever possible (or to
translate and back-translate measures).
Owing to limited resources, there were a high number of thera-
pists involved in the delivery of NET and trial assessments in this
study. This may have led to some inconsistencies across treatment
and assessments. Treatment model fidelity was closely monitored
through supervision, but the lack of an objective structured fidelity
rating was a limitation of this study.
In addition, some individuals received more than the allocated
number of NET (or non-NET) sessions, because clinicians used
their discretion to extend the course of therapy where this was clin-
ically indicated, where participants missed or cancelled sessions, or
where additional non-therapy sessions were required to address
practical issues. This led to an extended average period of time
over which therapy was delivered (over 7months), resulting in a dis-
crepancy with the control wait-list period, which was maintained at
5 months (the original estimated duration of therapy). This may
have influenced the results of the study to some degree. The NET
session number protocol should be monitored and adhered to
more closely in any full-scale trial, which should be more possible
if practical support is available consistently to all participants.
Consideration should also be given to whether more flexibility is
needed in the number of sessions offered for individuals with very
chronic trauma histories. To address these procedural issues, it is
recommended that dedicated trial clinicians are identified to under-
take any assessment or therapy delivery within future RCTs.
In conclusion, the results of this study indicate that a full-scale
RCT is likely to be feasible with trafficking survivors in a real-world
clinical context. The findings build on the existing literature indicat-
ing that NET is an effective treatment for survivors of trafficking
presenting with PTSD and can bring about improvement in other
psychological symptoms. Future research should consider ways to
ensure the holistic needs of participants are met, to facilitate their
optimal engagement in any psychological intervention.
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